Forest Laboratories, Inc. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Forest Laboratories, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Forest Laboratories, Inc. - Product Pipeline Review - 2014', provides an overview of the Forest Laboratories, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Forest Laboratories, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Forest Laboratories, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Forest Laboratories, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Forest Laboratories, Inc.'s pipeline products

Reasons to buy

- Evaluate Forest Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Forest Laboratories, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Forest Laboratories, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Forest Laboratories, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Forest Laboratories, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Forest Laboratories, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Forest Laboratories, Inc. Snapshot 6
Forest Laboratories, Inc. Overview 6
Key Information 6
Key Facts 6
Forest Laboratories, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Forest Laboratories, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Forest Laboratories, Inc. - Pipeline Products Glance 16
Forest Laboratories, Inc. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Filing rejected/Withdrawn Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Forest Laboratories, Inc. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Forest Laboratories, Inc. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Forest Laboratories, Inc. - Drug Profiles 22
(memantine hydrochloride ER + donepezil hydrochloride) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(nebivolol + valsartan) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
levofloxacin 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
cariprazine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(aclidinium bromide + formoterol fumarate) 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
(ceftazidime + avibactam) 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
pancrelipase DR 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
(ceftaroline + avibactam) 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cebranopadol 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
memantine hydrochloride 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EUR-1100 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
linaclotide 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ATL-1222 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Forest Laboratories, Inc. - Pipeline Analysis 45
Forest Laboratories, Inc. - Pipeline Products by Target 45
Forest Laboratories, Inc. - Pipeline Products by Route of Administration 47
Forest Laboratories, Inc. - Pipeline Products by Molecule Type 48
Forest Laboratories, Inc. - Pipeline Products by Mechanism of Action 49
Forest Laboratories, Inc. - Recent Pipeline Updates 51
Forest Laboratories, Inc. - Dormant Projects 66
Forest Laboratories, Inc. - Discontinued Pipeline Products 67
Discontinued Pipeline Product Profiles 67
alvameline maleate 67
dexloxiglumide 67
ME-1036 67
oglemilast 67
radiprodil 68
Forest Laboratories, Inc. - Company Statement 69
Forest Laboratories, Inc. - Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Forest Laboratories, Inc., Key Information 6
Forest Laboratories, Inc., Key Facts 6
Forest Laboratories, Inc. - Pipeline by Indication, 2014 9
Forest Laboratories, Inc. - Pipeline by Stage of Development, 2014 10
Forest Laboratories, Inc. - Monotherapy Products in Pipeline, 2014 11
Forest Laboratories, Inc. - Combination Treatment Modalities in Pipeline, 2014 12
Forest Laboratories, Inc. - Partnered Products in Pipeline, 2014 13
Forest Laboratories, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Forest Laboratories, Inc. - Pre-Registration, 2014 16
Forest Laboratories, Inc. - Filing rejected/Withdrawn, 2014 17
Forest Laboratories, Inc. - Phase III, 2014 18
Forest Laboratories, Inc. - Phase II, 2014 19
Forest Laboratories, Inc. - Phase I, 2014 20
Forest Laboratories, Inc. - Preclinical, 2014 21
Forest Laboratories, Inc. - Pipeline by Target, 2014 46
Forest Laboratories, Inc. - Pipeline by Route of Administration, 2014 47
Forest Laboratories, Inc. - Pipeline by Molecule Type, 2014 48
Forest Laboratories, Inc. - Pipeline Products by Mechanism of Action, 2014 50
Forest Laboratories, Inc. - Recent Pipeline Updates, 2014 51
Forest Laboratories, Inc. - Dormant Developmental Projects,2014 66
Forest Laboratories, Inc. - Discontinued Pipeline Products, 2014 67
Forest Laboratories, Inc., Other Locations 71
Forest Laboratories, Inc., Subsidiaries 72